1
|
Unsal Tan O, Moncol J, Durantel D. Design, Synthesis and Evaluation of Novel 4‐(4‐Chlorobenzyl)‐6‐methylpyridazin‐3(2
H
)‐one Derivatives as Hepatitis B Virus Inhibitors. ChemistrySelect 2022. [DOI: 10.1002/slct.202203164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Oya Unsal Tan
- Department of Pharmaceutical Chemistry Faculty of Pharmacy Hacettepe University Ankara Turkey
| | - Jan Moncol
- Department of Inorganic Chemistry Faculty of Chemical and Food Technology Slovak University of Technology Bratislava Slovakia
| | - David Durantel
- INSERM U1052 Cancer Research Center of Lyon (CRCL) University of Lyon (UCBL1) CNRS UMR 5286, Centre Léon Bérard 69008 Lyon France
- INSERM U1111 International Center for Infectiology Research (CIRI) CNRS UMR_5308 University of Lyon (UCBL1) Lyon France
| |
Collapse
|
2
|
Wang Z, Cherukupalli S, Xie M, Wang W, Jiang X, Jia R, Pannecouque C, De Clercq E, Kang D, Zhan P, Liu X. Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. J Med Chem 2022; 65:3729-3757. [PMID: 35175760 DOI: 10.1021/acs.jmedchem.1c01758] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Currently, HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a major component of the highly active anti-retroviral therapy (HAART) regimen. However, the occurrence of drug-resistant strains and adverse reactions after long-term usage have inevitably compromised the clinical application of NNRTIs. Therefore, the development of novel inhibitors with distinct anti-resistance profiles and better pharmacological properties is still an enormous challenge. Herein, we summarize state-of-the-art medicinal chemistry strategies for the discovery of potent NNRTIs, such as structure-based design strategies, contemporary computer-aided drug design, covalent-binding strategies, and the application of multi-target-directed ligands. The strategies described here will facilitate the identification of promising HIV-1 NNRTIs.
Collapse
Affiliation(s)
- Zhao Wang
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China
| | - Srinivasulu Cherukupalli
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China
| | - Minghui Xie
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China
| | - Wenbo Wang
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China
| | - Xiangyi Jiang
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China
| | - Ruifang Jia
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China
| | - Christophe Pannecouque
- Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, K.U. Leuven, Herestraat 49 Postbus 1043 (09.A097), B-3000 Leuven, Belgium
| | - Erik De Clercq
- Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, K.U. Leuven, Herestraat 49 Postbus 1043 (09.A097), B-3000 Leuven, Belgium
| | - Dongwei Kang
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China.,China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China
| | - Peng Zhan
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China.,China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China
| | - Xinyong Liu
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China.,China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China
| |
Collapse
|
3
|
Du X, Hou H, Zhao Y, Sheng S, Chen J. Rhodium(III)-Catalyzed Alkynylation of 4-Arylphthalazin-1(2 H
)-one Scaffolds via C-H Bond Activation. European J Org Chem 2020. [DOI: 10.1002/ejoc.201901731] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Xuxin Du
- Key Laboratory of Functional Small Organic Molecules; Ministry of Education and College of Chemistry & Chemical Engineering; Jiangxi Normal University; 330022 Nanchang P. R. China
| | - Hongcen Hou
- Key Laboratory of Functional Small Organic Molecules; Ministry of Education and College of Chemistry & Chemical Engineering; Jiangxi Normal University; 330022 Nanchang P. R. China
| | - Yongli Zhao
- Key Laboratory of Functional Small Organic Molecules; Ministry of Education and College of Chemistry & Chemical Engineering; Jiangxi Normal University; 330022 Nanchang P. R. China
| | - Shouri Sheng
- Key Laboratory of Functional Small Organic Molecules; Ministry of Education and College of Chemistry & Chemical Engineering; Jiangxi Normal University; 330022 Nanchang P. R. China
| | - Junmin Chen
- Key Laboratory of Functional Small Organic Molecules; Ministry of Education and College of Chemistry & Chemical Engineering; Jiangxi Normal University; 330022 Nanchang P. R. China
| |
Collapse
|
4
|
Wang Y, Wang J, Zhong P, Li Y, Lai CC, He Y. Molecular insight into the interaction mechanisms of an annulated pyrazole (DB08446) with HIV-1 RT: a QM and QM/QM′ study. MONATSHEFTE FUR CHEMIE 2018. [DOI: 10.1007/s00706-018-2239-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
5
|
Akhtar W, Shaquiquzzaman M, Akhter M, Verma G, Khan MF, Alam MM. The therapeutic journey of pyridazinone. Eur J Med Chem 2016; 123:256-281. [DOI: 10.1016/j.ejmech.2016.07.061] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Revised: 07/20/2016] [Accepted: 07/24/2016] [Indexed: 11/17/2022]
|
6
|
Yang L, Zhu Y, Shui M, Zhou T, Cai Y, Wang W, Xu F, Niu Y, Wang C, Zhang JL, Xu P, Yuan L, Liang L. Rational Design of Fluorescent Phthalazinone Derivatives for One- and Two-Photon Imaging. Chemistry 2016; 22:12363-70. [DOI: 10.1002/chem.201601499] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Indexed: 12/13/2022]
Affiliation(s)
- Lingfei Yang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
- Medical and Healthy Analysis Center; Peking University; Beijing P. R. China
| | - Yuanjun Zhu
- Department of Molecular and Cellular Pharmacology; School of Pharmaceutical Sciences; Peking University; Beijing P. R. China
| | - Mengyang Shui
- Department of Molecular and Cellular Pharmacology; School of Pharmaceutical Sciences; Peking University; Beijing P. R. China
| | - Tongliang Zhou
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Yuanbo Cai
- Beijing National Laboratory for Molecular Science; State Key Laboratory of Rare Earth Materials Chemistry and Applications; College of Chemistry and Molecular Engineering; Peking University; Beijing P. R.China
| | - Wei Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Fengrong Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Yan Niu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Chao Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Jun-Long Zhang
- Beijing National Laboratory for Molecular Science; State Key Laboratory of Rare Earth Materials Chemistry and Applications; College of Chemistry and Molecular Engineering; Peking University; Beijing P. R.China
| | - Ping Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Lan Yuan
- Medical and Healthy Analysis Center; Peking University; Beijing P. R. China
| | - Lei Liang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| |
Collapse
|
7
|
Yang L, Wang W, Sun Q, Xu F, Niu Y, Wang C, Liang L, Xu P. Development of novel proteasome inhibitors based on phthalazinone scaffold. Bioorg Med Chem Lett 2016; 26:2801-2805. [PMID: 27158142 DOI: 10.1016/j.bmcl.2016.04.067] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Revised: 04/11/2016] [Accepted: 04/23/2016] [Indexed: 11/18/2022]
Abstract
In this study we designed a series of proteasome inhibitors using pyridazinone as initial scaffold, and extended the structure with rational design by computer aided drug design (CADD). Two different synthetic routes were explored and the biological evaluation of the phthalazinone derivatives was investigated. Most importantly, electron positive triphenylphosphine group was first introduced in the structure of proteasome inhibitors and potent inhibition was achieved. As 6c was the most potent inhibitor of proteasome, we examined the structure-activity relationship (SAR) of 6c analogs.
Collapse
Affiliation(s)
- Lingfei Yang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Wei Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Qi Sun
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Fengrong Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Yan Niu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Chao Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Lei Liang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China.
| | - Ping Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| |
Collapse
|
8
|
|
9
|
Meng Q, Liu N, Huang B, Zhan P, Liu X. Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419. Expert Opin Ther Pat 2015; 25:1477-86. [PMID: 26415039 DOI: 10.1517/13543776.2016.1088832] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Diarylpyrimidine (DAPY) derivatives, one family of HIV non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) with superior activities against wild-type (WT) HIV-1 and NNRTI-resistant strains, have attracted much attention in the past decade. A series of DAPY derivatives featuring a fluorine atom on the central ring were reported as novel NNRTIs in the patent WO2014072419. Some compounds exhibited robust potency against both WT and mutant strains, which were approximately equal to or higher than those of the reference drug TMC120. Moreover, it has become evident that fluorinated molecules have a remarkable record in many other potent NNRTIs. Thus, this survey provides a sampling of renowned fluorinated NNRTIs and their mode of action, with an analysis clarifying the functional roles and impact of fluorine substitution on antiviral potency. We envision that fluorinated NNRTIs will play a continuing role in affording anti-HIV drug candidates for therapeutic applications.
Collapse
Affiliation(s)
- Qing Meng
- a Shandong University, School of Pharmaceutical Sciences, Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry , 44, West Culture Road, 250012, Jinan, Shandong, P. R. China ,
| | - Na Liu
- a Shandong University, School of Pharmaceutical Sciences, Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry , 44, West Culture Road, 250012, Jinan, Shandong, P. R. China ,
| | - Boshi Huang
- a Shandong University, School of Pharmaceutical Sciences, Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry , 44, West Culture Road, 250012, Jinan, Shandong, P. R. China ,
| | | | - Xinyong Liu
- a Shandong University, School of Pharmaceutical Sciences, Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry , 44, West Culture Road, 250012, Jinan, Shandong, P. R. China ,
| |
Collapse
|
10
|
Li W, Li X, De Clercq E, Zhan P, Liu X. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif. Eur J Med Chem 2015; 102:167-79. [DOI: 10.1016/j.ejmech.2015.07.043] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Revised: 07/20/2015] [Accepted: 07/22/2015] [Indexed: 11/26/2022]
|
11
|
Mao JH, Wang ZT, Wang ZY, Cheng Y. N-Heterocyclic Carbene-Catalyzed Oxidative Annulations of α,β-Unsaturated Aldehydes with Hydrazones: Selective Synthesis of Optically Active 4,5-Dihydropyridazin-3-ones and Pyridazin-3-ones. J Org Chem 2015; 80:6350-9. [PMID: 26019007 DOI: 10.1021/acs.joc.5b00784] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A novel and efficient method for the highly enantioselective synthesis of chiral 4,5-dihydropyridazin-3-one derivatives has been developed based on the chiral N-heterocyclic carbene-catalyzed oxidative annulation between α,β-unsaturated aldehydes and hydrazones. Meanwhile, the selective synthesis of either 4,5-dihydropyridazin-3-ones or pyridazin-3-one derivatives from the same reactants has been achieved by simply varying catalytic and reaction conditions.
Collapse
Affiliation(s)
- Jian-Hui Mao
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| | - Zi-Tian Wang
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| | - Zhan-Yong Wang
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| | - Ying Cheng
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| |
Collapse
|
12
|
Lou Y, Sweeney ZK, Kuglstatter A, Davis D, Goldstein DM, Han X, Hong J, Kocer B, Kondru RK, Litman R, McIntosh J, Sarma K, Suh J, Taygerly J, Owens TD. Finding the perfect spot for fluorine: Improving potency up to 40-fold during a rational fluorine scan of a Bruton’s Tyrosine Kinase (BTK) inhibitor scaffold. Bioorg Med Chem Lett 2015; 25:367-71. [DOI: 10.1016/j.bmcl.2014.11.030] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2014] [Revised: 11/05/2014] [Accepted: 11/07/2014] [Indexed: 10/24/2022]
|
13
|
Wang W, Liang L, Xu F, Huang W, Niu Y, Sun Q, Xu P. Ruthenium-Catalyzed Switchable N-H/C-H Alkenylation of 6-Phenyl(dihydro)pyridazinones with Alkynes. European J Org Chem 2014. [DOI: 10.1002/ejoc.201402986] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
14
|
Kandile NG, Zaky HT. New pyrano[2,3-c]pyridazine derivatives with antimicrobial activity synthesized using piperidine as the organocatalyst. J Enzyme Inhib Med Chem 2014; 30:44-51. [PMID: 24666292 DOI: 10.3109/14756366.2013.877896] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
A simple and efficient method for the synthesis of highly diverse pyrano[2,3-c]pyridazines was achieved by a one pot multicomponent reaction using piperidine as the organocatalyst. The synthesis of a series of heterocyclic derivatives with varying functionality (e.g. thiazine, tetrazole and pyrimidine) incorporating the pyrano[2,3-c]pyridazine moiety were achieved via reaction of 2a-e with different reagents. The structures of the synthesized derivatives were elucidated by FTIR, MS, (1)H and (13)C NMR spectroscopy. A number of the newly synthesized targeted compounds 2b-e, 3a-c and 4a-c were evaluated for their in vitro antibacterial activity and were compared with chloramphenicol and nystatin as broad spectrum reference standard antibiotics. Tests were carried out against Staphylococcus aureus (MTCC3160) and Enterococcusi fecalis as Gram-positive bacteria, and Escherichia coli (MTCC1652) and Klebsiella pneumonia as Gram-negative bacteria. Antifungal potential against Candida albicans, and Aspergillus albicans strains were also evaluated. The results revealed that compounds 3a and 3c showed strong significant activity relative to the reference against these bacterial and fungal strains.
Collapse
Affiliation(s)
- Nadia G Kandile
- Department of Chemistry, Faculty of Women, Ain Shams University , Heliopolis, Cairo , Egypt
| | | |
Collapse
|
15
|
Liang L, Yang G, Xu F, Niu Y, Sun Q, Xu P. Copper-Catalyzed Aerobic Dehydrogenation of C-C to C=C Bonds in the Synthesis of Pyridazinones. European J Org Chem 2013. [DOI: 10.1002/ejoc.201300640] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
16
|
Alkylation and 1,3-Dipolar Cycloaddition of 6-Styryl-4,5-dihydro-2 H-pyridazin-3-one: Synthesis of Novel N-Substituted Pyridazinones and Triazolo[4,3-b]pyridazinones. J CHEM-NY 2013. [DOI: 10.1155/2013/636280] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Some newN-substituted pyridazinones and triazolo[4,3-b]pyridazinones were synthesized, respectively, by simple alkylation and 1,3-dipolar cycloaddition of pyridazin-3-one with nitrile imines. The regioselectivity of the reactions was ascertained by1H,13C NMR spectroscopy and X-ray diffraction of the synthesized compounds.
Collapse
|
17
|
Villaseñor AG, Wong A, Shao A, Garg A, Donohue TJ, Kuglstatter A, Harris SF. Nanolitre-scale crystallization using acoustic liquid-transfer technology. ACTA CRYSTALLOGRAPHICA. SECTION D, BIOLOGICAL CRYSTALLOGRAPHY 2012; 68:893-900. [PMID: 22868754 PMCID: PMC3413209 DOI: 10.1107/s0907444912016617] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/20/2012] [Accepted: 04/16/2012] [Indexed: 11/11/2022]
Abstract
Focused acoustic energy allows accurate and precise liquid transfer on scales from picolitre to microlitre volumes. This technology was applied in protein crystallization, successfully transferring a diverse set of proteins as well as hundreds of precipitant solutions from custom and commercial crystallization screens and achieving crystallization in drop volumes as small as 20 nl. Only higher concentrations (>50%) of 2-methyl-2,4-pentanediol (MPD) appeared to be systematically problematic in delivery. The acoustic technology was implemented in a workflow, successfully reproducing active crystallization systems and leading to the discovery of crystallization conditions for previously uncharacterized proteins. The technology offers compelling advantages in low-nanolitre crystallization trials by providing significant reagent savings and presenting seamless scalability for those crystals that require larger volume optimization experiments using the same vapor-diffusion format.
Collapse
Affiliation(s)
- Armando G Villaseñor
- Department of Discovery Technologies, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, CA 94304, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
Design, synthesis and antiviral activity of novel pyridazines. Eur J Med Chem 2012; 54:33-41. [DOI: 10.1016/j.ejmech.2012.04.020] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2012] [Revised: 04/09/2012] [Accepted: 04/12/2012] [Indexed: 11/17/2022]
|
19
|
Bollini M, Domaoal RA, Thakur VV, Gallardo-Macias R, Spasov KA, Anderson KS, Jorgensen WL. Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J Med Chem 2011; 54:8582-91. [PMID: 22081993 DOI: 10.1021/jm201134m] [Citation(s) in RCA: 101] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A 5-μM docking hit has been optimized to an extraordinarily potent (55 pM) non-nucleoside inhibitor of HIV reverse transcriptase. Use of free energy perturbation (FEP) calculations to predict relative free energies of binding aided the optimizations by identifying optimal substitution patterns for phenyl rings and a linker. The most potent resultant catechol diethers feature terminal uracil and cyanovinylphenyl groups. A halogen bond with Pro95 likely contributes to the extreme potency of compound 42. In addition, several examples are provided illustrating failures of attempted grafting of a substructure from a very active compound onto a seemingly related scaffold to improve its activity.
Collapse
Affiliation(s)
- Mariela Bollini
- Department of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States
| | | | | | | | | | | | | |
Collapse
|
20
|
Besada P, Costas T, Vila N, Chessa C, Terán C. Synthesis and complete assignment of the 1H and 13C NMR spectra of 6-substituted and 2,6-disubstituted pyridazin-3(2H)-ones. MAGNETIC RESONANCE IN CHEMISTRY : MRC 2011; 49:437-442. [PMID: 21452351 DOI: 10.1002/mrc.2755] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2010] [Revised: 02/17/2011] [Accepted: 02/17/2011] [Indexed: 05/30/2023]
Abstract
Several pyridazin-3(2H)-one derivatives were synthesized starting from alkyl furans using oxidation with singlet oxygen to give 4-methoxy or 4-hydroxybutenolides, key intermediates of the synthetic strategy followed. For all pyridazinones reported, a complete assignment of the (1)H and (13)C NMR spectra using one- and two-dimensional NMR spectroscopic methods, which included NOE, DEPT, COSY, HSQC and HMBC experiments, was accomplished. Correlations between the chemical shifts of the heterocyclic ring atoms and substituents at N-2 and C-6 were analyzed.
Collapse
Affiliation(s)
- Pedro Besada
- Departamento de Química Orgánica, Facultade de Química, Universidade de Vigo, 36310 Vigo, Spain.
| | | | | | | | | |
Collapse
|
21
|
Gu SX, Zhang X, He QQ, Yang LM, Ma XD, Zheng YT, Yang SQ, Chen FE. Synthesis and biological evaluation of naphthyl phenyl ethers (NPEs) as novel nonnucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 2011; 19:4220-6. [DOI: 10.1016/j.bmc.2011.05.060] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2011] [Revised: 05/26/2011] [Accepted: 05/27/2011] [Indexed: 10/18/2022]
|
22
|
Zhan P, Chen X, Li D, Fang Z, De Clercq E, Liu X. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 2011; 33 Suppl 1:E1-72. [PMID: 21523792 DOI: 10.1002/med.20241] [Citation(s) in RCA: 153] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) nowadays represent very potent and most promising anti-AIDS agents that specifically target the HIV-1 reverse transcriptase (RT). However, the effectiveness of NNRTI drugs can be hampered by rapid emergence of drug-resistant viruses and severe side effects upon long-term use. Therefore, there is an urgent need to develop novel, highly potent NNRTIs with broad spectrum antiviral activity and improved pharmacokinetic properties, and more efficient strategies that facilitate and shorten the drug discovery process would be extremely beneficial. Fortunately, the structural diversity of NNRTIs provided a wide space for novel lead discovery, and the pharmacophore similarity of NNRTIs gave valuable hints for lead discovery and optimization. More importantly, with the continued efforts in the development of computational tools and increased crystallographic information on RT/NNRTI complexes, structure-based approaches using a combination of traditional medicinal chemistry, structural biology, and computational chemistry are being used increasingly in the design of NNRTIs. First, this review covers two decades of research and development for various NNRTI families based on their chemical scaffolds, and then describes the structural similarity of NNRTIs. We have attempted to assemble a comprehensive overview of the general approaches in NNRTI lead discovery and optimization reported in the literature during the last decade. The successful applications of medicinal chemistry strategies, crystallography, and computational tools for designing novel NNRTIs are highlighted. Future directions for research are also outlined.
Collapse
Affiliation(s)
- Peng Zhan
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, PR China
| | | | | | | | | | | |
Collapse
|
23
|
Qin B, Jiang X, Lu H, Tian X, Barbault F, Huang L, Qian K, Chen CH, Huang R, Jiang S, Lee KH, Xie L. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem 2010; 53:4906-16. [PMID: 20527972 DOI: 10.1021/jm1002952] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
By using structure-based drug design and isosteric replacement, diarylaniline and 1,5-diarylbenzene-1,2-diamine derivatives were synthesized and evaluated against wild type HIV-1 and drug-resistant viral strains, resulting in the discovery of diarylaniline derivatives as a distinct class of next-generation HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) agents. The most promising compound 37 showed significant EC(50) values of 0.003-0.032 microM against HIV-1 wild-type strains and of 0.005-0.604 microM against several drug-resistant strains. Current results also revealed important structure-activity relationship (SAR) conclusions for diarylanilines and strongly support our hypothesis that an NH(2) group on the central benzene ring ortho to the aniline moiety is crucial for interaction with K101 of the NNRTI binding site in HIV-1 RT, likely by forming H-bonds with K101. Furthermore, molecular modeling studies with molecular mechanism/general Born surface area (MM/GBSA) technology demonstrated the rationality of our hypothesis.
Collapse
Affiliation(s)
- Bingjie Qin
- Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Rich RL, Myszka DG. Grading the commercial optical biosensor literature-Class of 2008: 'The Mighty Binders'. J Mol Recognit 2010; 23:1-64. [PMID: 20017116 DOI: 10.1002/jmr.1004] [Citation(s) in RCA: 109] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Optical biosensor technology continues to be the method of choice for label-free, real-time interaction analysis. But when it comes to improving the quality of the biosensor literature, education should be fundamental. Of the 1413 articles published in 2008, less than 30% would pass the requirements for high-school chemistry. To teach by example, we spotlight 10 papers that illustrate how to implement the technology properly. Then we grade every paper published in 2008 on a scale from A to F and outline what features make a biosensor article fabulous, middling or abysmal. To help improve the quality of published data, we focus on a few experimental, analysis and presentation mistakes that are alarmingly common. With the literature as a guide, we want to ensure that no user is left behind.
Collapse
Affiliation(s)
- Rebecca L Rich
- Center for Biomolecular Interaction Analysis, University of Utah, Salt Lake City, UT 84132, USA
| | | |
Collapse
|
25
|
Davidson JP, Sarma K, Fishlock D, Welch MH, Sukhtankar S, Lee GM, Martin M, Cooper GF. A Synthesis of 3,5-Disubstituted Phenols. Org Process Res Dev 2010. [DOI: 10.1021/op900322u] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- James P. Davidson
- Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, U.S.A., Chemical Synthesis, Hoffmann-La Roche, 340 Kingsland Avenue, Nutley, New Jersey 07110, U.S.A
| | - Keshab Sarma
- Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, U.S.A., Chemical Synthesis, Hoffmann-La Roche, 340 Kingsland Avenue, Nutley, New Jersey 07110, U.S.A
| | - Dan Fishlock
- Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, U.S.A., Chemical Synthesis, Hoffmann-La Roche, 340 Kingsland Avenue, Nutley, New Jersey 07110, U.S.A
| | - Michael H. Welch
- Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, U.S.A., Chemical Synthesis, Hoffmann-La Roche, 340 Kingsland Avenue, Nutley, New Jersey 07110, U.S.A
| | - Sunil Sukhtankar
- Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, U.S.A., Chemical Synthesis, Hoffmann-La Roche, 340 Kingsland Avenue, Nutley, New Jersey 07110, U.S.A
| | - Gary M. Lee
- Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, U.S.A., Chemical Synthesis, Hoffmann-La Roche, 340 Kingsland Avenue, Nutley, New Jersey 07110, U.S.A
| | - Michael Martin
- Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, U.S.A., Chemical Synthesis, Hoffmann-La Roche, 340 Kingsland Avenue, Nutley, New Jersey 07110, U.S.A
| | - Gary F. Cooper
- Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, U.S.A., Chemical Synthesis, Hoffmann-La Roche, 340 Kingsland Avenue, Nutley, New Jersey 07110, U.S.A
| |
Collapse
|
26
|
Kennedy-Smith JJ, Arora N, Billedeau JR, Fretland J, Hang JQ, Heilek GM, Harris SF, Hirschfeld D, Javanbakht H, Li Y, Liang W, Roetz R, Smith M, Su G, Suh JM, Villaseñor AG, Wu J, Yasuda D, Klumpp K, Sweeney ZK. Synthesis and biological activity of new pyridone diaryl ether non-nucleoside inhibitors of HIV-1 reverse transcriptase. MEDCHEMCOMM 2010. [DOI: 10.1039/c0md00009d] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
27
|
Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J Mol Model 2009; 16:1169-78. [PMID: 20013136 DOI: 10.1007/s00894-009-0625-8] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2009] [Accepted: 11/06/2009] [Indexed: 10/20/2022]
Abstract
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are allosteric inhibitors of the HIV-1 reverse transcriptase. Recently a series of Triazolinone and Pyridazinone were reported as potent inhibitors of HIV-1 wild type reverse transcriptase. In the present study, docking and 3D quantitative structure activity relationship (3D QSAR) studies involving comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were performed on 31 molecules. Ligands were built and minimized using Tripos force field and applying Gasteiger-Hückel charges. These ligands were docked into protein active site using GLIDE 4.0. The docked poses were analyzed; the best docked poses were selected and aligned. CoMFA and CoMSIA fields were calculated using SYBYL6.9. The molecules were divided into training set and test set, a PLS analysis was performed and QSAR models were generated. The model showed good statistical reliability which is evident from the r2 nv, q2 loo and r2 pred values. The CoMFA model provides the most significant correlation of steric and electrostatic fields with biological activities. The CoMSIA model provides a correlation of steric, electrostatic, acceptor and hydrophobic fields with biological activities. The information rendered by 3D QSAR model initiated us to optimize the lead and design new potential inhibitors.
Collapse
|
28
|
Loksha YM, Pedersen EB, Loddo R, La Colla P. Synthesis and anti-HIV-1 activity of 1-substiuted 6-(3-cyanobenzoyl) and [(3-cyanophenyl)fluoromethyl]-5-ethyl-uracils. Arch Pharm (Weinheim) 2009; 342:501-6. [PMID: 19637180 DOI: 10.1002/ardp.200900058] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
1-Substiuted 6-(3-cyanobenzoyl) and [(3-cyanophenyl)fluoromethyl]-5-ethyl-uracils were synthesized and evaluated in cell-based assays against HIV-1 wild-type and its clinically relevant non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutants. Some of the synthesized compounds showed activity against HIV-1 wild-type in the same range as Emivirine (MKC-442). 3-{[3-(Allyloxymethyl)-5-ethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl]fluoromethyl}-benzonitrile 11b showed moderate activity against the Y181C HIV-1 mutant strain.
Collapse
Affiliation(s)
- Yasser M Loksha
- Nucleic Acid Centre, Department of Physics and Chemistry, University of Southern Denmark, Odense M, Denmark
| | | | | | | |
Collapse
|
29
|
Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. Future Med Chem 2009; 1:1399-414. [DOI: 10.4155/fmc.09.100] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Surface plasmon resonance biosensor technology has come of age and become an important tool for drug discovery. It is a label-free biophysical technique for the kinetic analysis of molecular interactions that provides exceptionally information-rich data. Recent improvements in sensitivity, experimental design, data analysis and sample throughput makes it suitable for use throughout the drug-discovery process. This article outlines the use of SPR biosensor technology for small-molecule drug discovery and exemplifies how it complements other techniques. The technology is especially valuable for fragment-based lead discovery since it has the required sensitivity and throughput for screening of fragment libraries. Hits can be identified with respect to multiple criteria, defined by the experimental design used for screening. Expansion of hits and subsequent characterization and optimization of leads can be performed with a variety of experiments exploiting the kinetic resolution of the technology. Leads identified by this strategy can therefore be extensively characterized with respect to their interactions, with their target as well as with nontarget proteins. Although it may take some time for the methods to become well established, and for the research community to reach proficiency and fully embrace the information-rich data that can be obtained, it can be predicted that this technology will be widely used for drug discovery within the near future. It is expected that the technology will be particularly important for fragment-based strategies and integrated with other experimental technologies as well as with computational methods.
Collapse
|
30
|
Sweeney Z, Kennedy‐Smith J, Wu J, Arora N, Billedeau J, Davidson J, Fretland J, Hang J, Heilek G, Harris S, Hirschfeld D, Inbar P, Javanbakht H, Jernelius J, Jin Q, Li Y, Liang W, Roetz R, Sarma K, Smith M, Stefanidis D, Su G, Suh J, Villaseñor A, Welch M, Zhang F, Klumpp K. Diphenyl Ether Non‐Nucleoside Reverse Transcriptase Inhibitors with Excellent Potency Against Resistant Mutant Viruses and Promising Pharmacokinetic Properties. ChemMedChem 2009; 4:88-99. [DOI: 10.1002/cmdc.200800262] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Zachary K. Sweeney
- Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA), Fax: (+1) 650‐852‐1311
| | - Joshua J. Kennedy‐Smith
- Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA), Fax: (+1) 650‐852‐1311
| | - Jeffrey Wu
- Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA), Fax: (+1) 650‐852‐1311
| | - Nidhi Arora
- Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA), Fax: (+1) 650‐852‐1311
| | - J. Roland Billedeau
- Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA), Fax: (+1) 650‐852‐1311
| | - James P. Davidson
- Department of Chemical Synthesis, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Jennifer Fretland
- Department of Non‐Clinical Safety, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Julie Q. Hang
- Department of Viral Disease Biochemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Gabrielle M. Heilek
- Department of Viral Disease Biology, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Seth F. Harris
- Department of Discovery Sciences and Technologies, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Donald Hirschfeld
- Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA), Fax: (+1) 650‐852‐1311
| | - Petra Inbar
- Department of Discovery Pharmaceutics, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Hassan Javanbakht
- Department of Viral Disease Biology, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Jesper A. Jernelius
- Department of Chemical Synthesis, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Qingwu Jin
- Department of Chemical Synthesis, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Yu Li
- Department of Viral Disease Biochemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Weiling Liang
- Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA), Fax: (+1) 650‐852‐1311
| | - Ralf Roetz
- Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA), Fax: (+1) 650‐852‐1311
| | - Keshab Sarma
- Department of Chemical Synthesis, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Mark Smith
- Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA), Fax: (+1) 650‐852‐1311
| | - Dimitrio Stefanidis
- Department of Discovery Pharmaceutics, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Guoping Su
- Department of Viral Disease Biology, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Judy M. Suh
- Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA), Fax: (+1) 650‐852‐1311
| | - Armando G. Villaseñor
- Department of Discovery Sciences and Technologies, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Michael Welch
- Department of Chemical Synthesis, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Fang‐Jie Zhang
- Department of Chemical Synthesis, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| | - Klaus Klumpp
- Department of Viral Disease Biochemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304 (USA)
| |
Collapse
|
31
|
Manlove A, Groziak MP. Chapter 6.2: Six-Membered Ring Systems: Diazines and Benzo Derivatives. PROGRESS IN HETEROCYCLIC CHEMISTRY 2009. [DOI: 10.1016/s0959-6380(09)70040-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
|
32
|
Rossotti R, Rusconi S. Efficacy and resistance of recently developed non-nucleoside reverse transcriptase inhibitors for HIV-1. ACTA ACUST UNITED AC 2009. [DOI: 10.2217/17584310.3.1.63] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Since the introduction of the HAART, non-nucleoside reverse transcriptase inhibitors (NNRTIs) have played an essential role in treating HIV: their strong antiviral potency, good metabolic profile and low pill burden make them an ideal option in the design of an optimized triple drug regimen. Nonetheless, the currently approved NNRTIs (efavirenz and nevirapine) are weighed by peculiar toxicities, while a low genetic barrier and the development of cross-resistance significantly limits their use in cases of suboptimal adherence. Many drugs are in development and they are all designed with the aim to overcome resistance problems. In this review we present data on virological efficacy and resistance profiles of some of the most promising new molecules: some (such as rilpivirine) are close to being marketed, others are in Phase II trials (IDX899 and RDEA806), others again have just completed preclinical studies and are having their first clinical evaluations (RO-5028, UK-453061 and BILR-355 BS); etravirine is already approved by the US FDA, but it is still not licensed in Europe. Other new molecules (Merck MK-4965, GlaxoSmithKline GW678284 and a pyridazinone derivative by Roche), which are currently in early-development phases, are also briefly described.
Collapse
Affiliation(s)
- Roberto Rossotti
- Dipartimento di Scienze Cliniche, ‘Luigi Sacco’, Sezione di Malattie Infettive e Immunopatologia, University of Milan, 20157 Milan, Italy
| | - Stefano Rusconi
- Dipartimento di Scienze Cliniche, ‘Luigi Sacco’, Sezione di Malattie Infettive e Immunopatologia, University of Milan, 20157 Milan, Italy
| |
Collapse
|
33
|
Elworthy TR, Dunn JP, Hogg JH, Lam G, Saito YD, Silva TM, Stefanidis D, Woroniecki W, Zhornisky E, Zhou AS, Klumpp K. Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2008; 18:6344-7. [DOI: 10.1016/j.bmcl.2008.10.090] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2008] [Revised: 10/16/2008] [Accepted: 10/20/2008] [Indexed: 11/17/2022]
|
34
|
Sweeney ZK, Harris SF, Arora N, Javanbakht H, Li Y, Fretland J, Davidson JP, Billedeau JR, Gleason SK, Hirschfeld D, Kennedy-Smith JJ, Mirzadegan T, Roetz R, Smith M, Sperry S, Suh JM, Wu J, Tsing S, Villaseñor AG, Paul A, Su G, Heilek G, Hang JQ, Zhou AS, Jernelius JA, Zhang FJ, Klumpp K. Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase. J Med Chem 2008; 51:7449-58. [DOI: 10.1021/jm800527x] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Zachary K. Sweeney
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Seth F. Harris
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Nidhi Arora
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Hassan Javanbakht
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Yu Li
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Jennifer Fretland
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - James P. Davidson
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - J. Roland Billedeau
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Shelley K. Gleason
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Donald Hirschfeld
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Joshua J. Kennedy-Smith
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Taraneh Mirzadegan
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Ralf Roetz
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Mark Smith
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Sarah Sperry
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Judy M. Suh
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Jeffrey Wu
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Stan Tsing
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Armando G. Villaseñor
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Amber Paul
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Guoping Su
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Gabrielle Heilek
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Julie Q. Hang
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Amy S. Zhou
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Jesper A. Jernelius
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Fang-Jie Zhang
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| | - Klaus Klumpp
- Departments of Medicinal Chemistry, Discovery Sciences and Technologies, Viral Disease Biology, Viral Disease Biochemistry, Non-Clinical Safety, and Chemical Synthesis, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304
| |
Collapse
|
35
|
Sweeney ZK, Acharya S, Briggs A, Dunn JP, Elworthy TR, Fretland J, Giannetti AM, Heilek G, Li Y, Kaiser AC, Martin M, Saito YD, Smith M, Suh JM, Swallow S, Wu J, Hang JQ, Zhou AS, Klumpp K. Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase. Bioorg Med Chem Lett 2008; 18:4348-51. [DOI: 10.1016/j.bmcl.2008.06.080] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2008] [Revised: 06/20/2008] [Accepted: 06/24/2008] [Indexed: 11/27/2022]
|